For mismatch repair proficient/microsatellite stable (pMMR/MSS) colon and rectal cancer, immunotherapy has shown limited efficacy. Herein, we report exceptional responses observed with neoadjuvant botensilimab (
Sonderstrup, I.M.H., et al., Topoisomerase-1 and-2A gene copy numbers are elevated in mismatch repair- proficient colorectal cancers. Molecular ... Sonderstrup,IM Heeholm,Nygard,... 被引量: 0发表: 0年 Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary car...
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH) 基于免疫疗法的全新辅助治疗熟练错配修复或微卫星稳定的局部晚期直肠癌的随机II期试验(TORCH) ...
On the other hand, the majority of mCRC patients, characterized by a proficient mismatch repair system/microsatellite stable (pMMR/MSS) and POLE integrity (95%), has an immune-desert or immune-excluded (or “cold”) microenvironment, finally resulting in a blunted immune activation of tumour ...